
Mithila Drugs Private Limited
Manufacturer and trader of bulk drugs and intermediates since 1995 in Udaipur, Rajasthan.
Manufacturer and trader of bulk drugs and intermediates since 1995 in Udaipur, Rajasthan.
Mithila Drugs Private Limited (MDPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 13 February 1995 and has a history of 30 years. Its registered office is in Udaipur, Rajasthan, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.20 Cr and a paid-up capital of Rs 1.20 Cr.
The company currently has active open charges totaling ₹10.57 Cr. The company has closed loans amounting to ₹24.35 Cr, as per Ministry of Corporate Affairs (MCA) records.
Sanjay Jha, Arvind Jha, and Pramod Jha serve as directors at the Company.
Udaipur, Rajasthan, India
+91-XXXXXXXXXX
-
U24232RJ1995PTC009496
009496
Private Limited Indian Non-Government Company
13 Feb 1995
30 Sep 2023
31 Mar 2023
Unlisted
Roc Jaipur
Mithila Drugs Private Limited offers a wide range of products and services, including Cardiovascular Drugs & Medication, Antidiabetic Medicine, TB, Tumor & Cancer Drugs, Anti Cancer Injection, Common Disease Medicines, Injectable Products, Sexual Wellness Products, Contraceptives, Anti Cancer Medicines, Fertility Enhancer.
Name | Designation | Appointment Date | Status |
---|---|---|---|
Sanjay Jha ![]() | Director | 01-Dec-1996 | Current |
Arvind Jha ![]() | Director | 09-Sep-2008 | Current |
Pramod Jha ![]() | Director | 13-Feb-1995 | Current |
Mithila Drugs Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 15.66% decrease. The company also saw a substantial fall in profitability, with a 406.65% decrease in profit. The company's net worth observed a substantial decline by a decrease of 17.59%.
Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
---|---|---|---|---|---|---|---|
Total Revenue |
| ||||||
Revenue from Operations |
| ||||||
Total Assets |
| ||||||
Profit or Loss |
| ||||||
Net Worth |
| ||||||
EBITDA |
|
In 2023, Mithila Drugs had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
₹10.57 Cr
₹24.35 Cr
Date | Lender | Amount | Status |
---|---|---|---|
06 Jul 2020 | State Bank Of India | ₹4.70 M | Open |
06 Jul 2020 | State Bank Of India | ₹2.70 M | Open |
29 Dec 2016 | Others | ₹9.83 Cr | Open |
20 Jul 2020 | Others | ₹1.50 M | Satisfied |
29 Sep 2009 | State Bank Of Bikaner And Jaipur | ₹1.00 Cr | Satisfied |
Unlock and access historical data on people associated with Mithila Drugs, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Gain comprehensive insights into the Deals and Valuation data of Mithila Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Mithila Drugs's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
A charge registered on 20 Jul 2020 via Charge ID 100377981 with Others was fully satisfied on 13 Oct 2023.
Mithila Drugs Private Limited last Annual general meeting of members was held on 30 Sep 2023 as per latest MCA records.
Mithila Drugs Private Limited has filed its annual Financial statements for the year ended 31 Mar 2023 with Roc Jaipur.
A charge with Others amounted to Rs. 0.15 Cr with Charge ID 100377981 was registered on 20 Jul 2020.
A charge with State Bank Of India amounted to Rs. 0.47 Cr with Charge ID 100351109 was registered on 06 Jul 2020.
A charge with State Bank Of India amounted to Rs. 0.27 Cr with Charge ID 100351110 was registered on 06 Jul 2020.
Mithila Drugs Private Limited was incorporated on 13 Feb 1995.
The authorized share capital of Mithila Drugs Private Limited is ₹ 1.20 Cr and paid-up capital is ₹ 1.20 Cr.
Currently 3 directors are associated with Mithila Drugs Private Limited.
As per Ministry of Corporate Affairs (Mca), the registered address of Mithila Drugs Private Limited is Road No. 2 F-70 M.I.A., India, Udaipur, Rajasthan, 313002.
The corporate identification number (CIN) of Mithila Drugs Private Limited is U24232RJ1995PTC009496 and the company number is 009496 as per Ministry of Corporate Affairs (MCA).
According to the financial reports for the fiscal year 2023, the revenue trend for Mithila Drugs Private Limited has fallen by -15.66%.
The financial reports for the fiscal year 2023 indicates that The net worth of Mithila Drugs Private Limited has experienced an downturn of -17.59%.
As per the financial statements for fiscal Year 2023, The total open charges for Mithila Drugs Private Limited amount to ₹ 10.57 Cr.
The most recent Balance Sheet for Mithila Drugs Private Limited was filed with the ROC on 31 Mar 2023.
SN
RM
RJ
SD